Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial-Reference-Cited by-同舟云学术

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Published:2022-09 Issue:9 Volume:17 Page:1086-1097
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Piccirillo Maria Carmela,Bonanno Laura,Garassino Marina Chiara,Esposito Giovanna,Dazzi Claudio,Cavanna Luigi,Burgio Marco Angelo,Rosetti Francesco,Rizzato Simona,Morgillo Floriana,Cinieri Saverio,Veccia Antonello,Papi Maximilan,Tonini Giuseppe,Gebbia Vittorio,Ricciardi Serena,Pozzessere Daniele,Ferro Alessandra,Proto Claudia,Costanzo Raffaele,D’Arcangelo Manolo,Proietto Manuela,Gargiulo Piera,Di Liello Raimondo,Arenare Laura,De Marinis Filippo,Crinò Lucio,Ciardiello Fortunato,Normanno Nicola,Gallo Ciro,Perrone Francesco^ORCID,Gridelli Cesare,Morabito Alessandro

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance;Naumov;Clin Cancer Res,2009

2. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance;Li;Eur J Cancer,2017

3. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study;Seto;Lancet Oncol,2014

4. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial;Rosell;Lancet Respir Med,2017

5. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 randomized clinical trial;Stinchcombe;JAMA Oncol,2019

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer;American Journal of Clinical Oncology;2024-09-11

2. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

3. Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer;PLOS ONE;2024-06-27

4. Ileal perforation at the site of peritoneal metastasis with intestinal infiltration by dual EGFR-VEGF pathway inhibition in an EGFR-mutant non-small cell lung cancer patient;International Cancer Conference Journal;2024-06-13

5. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer;Cancers;2024-06-12